Actively Recruiting
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
Led by Hebei Senlang Biotechnology Inc., Ltd. · Updated on 2025-06-24
50
Participants Needed
1
Research Sites
273 weeks
Total Duration
On this page
Sponsors
H
Hebei Senlang Biotechnology Inc., Ltd.
Lead Sponsor
H
Hebei Taihe Chunyu Biotechnology Co., Ltd
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the tolerability and safety of CAR-T technology in patients with relapsed or refractory hematolymphoid malignancies.
CONDITIONS
Official Title
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent and willingness to follow study visits, treatment, and tests
- Diagnosed with relapsed or refractory lymphoma, leukemia, or myeloma
- Tumor cells express targets for CAR-T therapy confirmed by flow cytometry or immunohistochemical tests
- Age between 14 and 75 years, any gender
- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less
- Hemoglobin level at least 70g/L (blood transfusions allowed)
- Adequate liver, kidney, heart, and lung function as defined by specific lab and clinical criteria
- For T cell tumor patients, peripheral blood tumor cells must meet specific immunophenotype criteria
- Agreement to use contraception during and for six months after the study if pregnancy is planned
- Expected survival longer than 3 months
- Understanding and signing of informed consent form
You will not qualify if you...
- Severe heart failure
- History of severe lung damage
- Presence of other advanced cancers
- Severe or uncontrolled infections
- Severe autoimmune diseases or congenital immune deficiency
- Active hepatitis B or C infection
- HIV or syphilis infection
- History of severe allergic reactions to biological products including antibiotics
- Hematopoietic stem cell transplant within 6 months prior to allogeneic transplant
- Previous CAR-T or gene-modified cell therapy before screening
- Any condition increasing risk or interfering with study outcomes as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanxi Bethune Hospital
Taiyuan, Shanxi, China
Actively Recruiting
Research Team
W
Weiwei w Tian, MD
CONTACT
N
Na Kuang, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here